Immunosuppressants in T1D Research: Expert Opinions from Diabetes Pharmacist Diana Isaacs
Current research on type 1 diabetes (T1D) and islet cells often uses immunosuppressant drugs to prevent rejection of implanted cells. While some studies…
The 2025 T1DX-QI Learning Session: Driving Better Diabetes Care
The 2025 T1D Exchange Quality Improvement Collaborative (T1DX-QI) Learning Session was held in Atlanta on November 11–12, drawing clinicians, researchers,…
Barriers to Care in Aging: Voices from the T1D Community
We recognize Jaime Lucove, Vice President Real-World Evidence and Research at T1D Exchange, for her editorial contributions to the development…
What is Diabetes-Related Neuropathy? A Nurse Explains
AI-assisted summary: With diabetes-related neuropathy, glucose levels can affect how healthy nerves function. The condition happens when elevated glucose levels…
Clinical Research in Recent-Onset Type 1 Diabetes
In 2022, the drug teplizumab (Tzield®) was approved to delay the need for insulin therapy in people living with stage…
Then & Now: Changes in T1D Treatments Over the Past 6 Years
We’re continuing to celebrate 6 years of the T1D Exchange Registry! In honor of the anniversary of our online registry,…
Then & Now: T1D Tech in 6 Years of the T1D Exchange Registry
We’re celebrating six years of the T1D Exchange Registry! Since its online launch in 2019, we’ve gathered the stories of…
Inhaled Insulin Insights from T1D Exchange at ADCES 2025
This year, the Association of Diabetes Care & Education Specialists (ADCES) conference was held in Phoenix, AZ, from August 8 to…
Jennifer Okemah: CDCES Takeaways from ADA 2025
Chicago, IL, hosted the 2025 American Diabetes Association (ADA) Scientific Sessions, bringing together a diverse community of experts dedicated to…
All About T1D Exchange Research at ADA’s 85th Scientific Sessions
From June 20 to 23, 2025, many of the world’s leading scientists in diabetes research gathered in Chicago, Illinois, for…
